PENTAMIDINE Drug Patent Profile

When do Pentamidine patents expire, and when can generic versions of Pentamidine launch?

Pentamidine is a drug marketed by Pai Holdings, X-gen Pharms Inc, Avet Lifesciences, Baxter Hlthcare, Hospira, Pharmobedient, and Watson Labs. and is included in eight NDAs.

The generic ingredient in PENTAMIDINE is pentamidine isethionate. There are fourteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the pentamidine isethionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pentamidine

A generic version of PENTAMIDINE was approved as pentamidine isethionate by PAI HOLDINGS on September 28^th, 2017.

Summary for PENTAMIDINE

US Patents:	0
Applicants:	7
NDAs:	8
Drug Prices:	Drug price information for PENTAMIDINE
DailyMed Link:	PENTAMIDINE at DailyMed

See drug prices for PENTAMIDINE

US Patents and Regulatory Information for PENTAMIDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pai Holdings	PENTAMIDINE ISETHIONATE	pentamidine isethionate	FOR SOLUTION;INHALATION	206667-001	Apr 24, 2019	AN	RX	No	No
Pharmobedient	PENTAMIDINE ISETHIONATE	pentamidine isethionate	INJECTABLE;INJECTION	206982-001	Mar 17, 2022		DISCN	No	No
Baxter Hlthcare	PENTAMIDINE ISETHIONATE	pentamidine isethionate	INJECTABLE;INJECTION	073617-001	Dec 18, 1995		DISCN	No	No
Watson Labs	PENTAMIDINE ISETHIONATE	pentamidine isethionate	INJECTABLE;INJECTION	074303-001	Aug 17, 1995		DISCN	No	No
X-gen Pharms Inc	PENTAMIDINE ISETHIONATE	pentamidine isethionate	FOR SOLUTION;INHALATION	206983-001	Jan 20, 2023	AN	RX	No	No
Avet Lifesciences	PENTAMIDINE ISETHIONATE	pentamidine isethionate	INJECTABLE;INJECTION	213806-001	Jan 7, 2021	AP	RX	No	No